A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (TROPICS-03)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 600
Summary
- Conditions
- Endometrial Cancer
- Head and Neck Squamous Cell Carcinoma
- Metastatic Non-Small Cell Lung Carcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is a multi-cohort, open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in adult subjects with metastatic solid tumors.
This is a multi-cohort, open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in adult subjects with metastatic solid tumors.
Tracking Information
- NCT #
- NCT03964727
- Collaborators
- Not Provided
- Investigators
- Study Chair: Cabilia Pichardo, MD Gilead Sciences
Get Well Soon